| Interpretable deep learning insights: Unveiling the role of 1 Gy volume on lymphopenia after radiotherapy in breast cancer F Chen, P Zhou, G Ren, EKW Lee, Q Liu, Y Shen, Y Wang, A El Helali, ... Radiotherapy and Oncology 197, 110333, 2024 | 1 | 2024 |
| Image analysis Uncovers associations between immune landscape, collagen structure, and neoadjuvant chemotherapy in high-grade serous ovarian carcinomas A Aggarwal, G Corredor, P Fu, T Pathak, T Mirtti, S Modesitt, TR Soong, ... Heliyon 10 (13), 2024 | | 2024 |
| Haplo-cord transplant. Realizing the potential of umbilical cord blood grafts.–A review of techniques and analysis of outcomes K van Besien, H Liu, S Margevicius, P Fu, A Artz, OK Chaekal, L Metheny, ... Leukemia & Lymphoma, 1-14, 2024 | | 2024 |
| Survival outcomes of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with platinum-based chemotherapy plus paclitaxel … K Burkitt, P Fu, S Margevicius Journal of Clinical Oncology 42 (16_suppl), e18010-e18010, 2024 | | 2024 |
| Surrogate endpoints and outcomes in modern small cell lung cancer trials. S Durer, P Fu, Z Chen, A Dowlati Journal of Clinical Oncology 42 (16_suppl), 8091-8091, 2024 | | 2024 |
| Neoadjuvant pazopanib with radiation therapy in patients with localized sarcoma: Experience from a sarcoma center. M Trybula, A Mangla, LD Rothermel, B Jonard, R Zuhour, A Nascimento, ... Journal of Clinical Oncology 42 (16_suppl), e23555-e23555, 2024 | | 2024 |
| Association of artificial intelligence–derived collagen disorder architecture (CoDA) features with survival outcome and objective response to immune checkpoint inhibitors in … R Nag, H Li, G Corredor, P Fu, S Khalighi, SM Steward-Tharp, MR Patel, ... Journal of Clinical Oncology 42 (16_suppl), 6061-6061, 2024 | | 2024 |
| Comprehensive analysis of the value of dynamic changes in ctDNA in SCLC. P Joseph, Z Chen, A Ajay, P Fu, A Dowlati Journal of Clinical Oncology 42 (16_suppl), 8107-8107, 2024 | | 2024 |
| Treatment outcomes in locally advanced, unresectable NSCLC treated with concurrent chemoradiation and PD-L1 consolidation: Real-world data from a NCI comprehensive cancer … MM Mirsky, HJ Lee, SP Margevicius, A Carsel, K Myers, K Zablonski, ... Journal of Clinical Oncology 42 (16_suppl), 8067-8067, 2024 | | 2024 |
| Assessment of blood-based tumor mutational burden on clinical outcomes in advanced breast and prostate cancer treated with immune checkpoint inhibitors P Barata, R Barnett, A Jang, S Lanka, P Fu, L Bucheit, H Babiker, A Bryce, ... | | 2024 |
| Deep Learning reveals lung shape differences on baseline chest CT between mild and severe COVID-19: A multi-site retrospective study A Hiremath, VS Viswanathan, K Bera, R Shiradkar, L Yuan, K Armitage, ... Computers in Biology and Medicine, 108643, 2024 | | 2024 |
| Computational Pathology Assessments of Cardiac Stromal Remodeling: Clinical Correlates and Prognostic Implications in Heart Transplantation E Peyster, C Yuan, S Arabyarmohammadi, P Lal, M Feldman, P Fu, ... Research Square, 2024 | | 2024 |
| Enhancing cardiovascular risk prediction through AI-enabled calcium-omics A Hoori, S Al-Kindi, T Hu, Y Song, H Wu, J Lee, N Tashtish, P Fu, ... Scientific Reports 14 (1), 11134, 2024 | | 2024 |
| Outcomes of initial therapy for synchronous brain metastases from small cell lung cancer: a single-institution retrospective analysis KV Chaung, MZ Kharouta, AJ Gross, P Fu, M Machtay, TR Hodges, ... Translational lung cancer research 13 (5), 1110, 2024 | | 2024 |
| Abstract PO5-17-08: Real world outcomes of neoadjuvant chemotherapy in ER-positive/PR-positive, HER2-negative breast cancer M Kurian, M Trybula, K Patell, G Guzik, S Margevicius, P Fu, A Montero, ... Cancer Research 84 (9_Supplement), PO5-17-08-PO5-17-08, 2024 | | 2024 |
| Abstract PO3-04-04: Long term survival of metastatic HER2 positive breast cancer patients with no radiographic evidence of disease (NED) on HER2 antibody therapy A Bennett, Z Chen, J Martin, N Mallat, P Fu, A Montero Cancer Research 84 (9_Supplement), PO3-04-04-PO3-04-04, 2024 | | 2024 |
| PD42-06 CXC MOTIF CHEMOKINE RECEPTOR AS A DIFFERENTIAL BIOMARKER IN RACIAL DISPARITIES OF PROSTATE CANCER AA Ahmed, S Verma, IM Atawia, DL Shen, GT MacLennan, P Fu, S Gupta Journal of Urology 211 (5S), e894, 2024 | | 2024 |
| Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis A Mangla, C Lee, MM Mirsky, M Wang, LD Rothermel, R Hoehn, ... JAMA oncology 10 (5), 612-620, 2024 | 1 | 2024 |
| Patients on Antithrombotic Agents with Small Bowel Bleeding–Yield of Small Bowel Capsule Endoscopy and Subsequent Management S Damjanovska, D Karb, A Chen, S Margevicius, P Fu, G Isenberg Digestive Diseases and Sciences, 1-7, 2024 | | 2024 |
| A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia LL Metheny, R Sobecks, C Cho, P Fu, S Margevicius, J Wang, L Ciarrone, ... Blood Advances 8 (6), 1384-1391, 2024 | 2 | 2024 |
Anant MadabhushiDepartment of Biomedical Engineering, Professor, Biomedical Engineering, Emory Univ & Georgia Tech在 emory.edu 的电子邮件经过验证
